Literature DB >> 8730492

Classification of the cryoglobulinemic syndrome.

F Invernizzi1, M Pietrogrande, B Sagramoso.   

Abstract

As cryoprecipitation is a laboratory artifact, it is necessary to identify those patients with mixed cryoglobulinemia who actually have the cryoglobulinemic syndrome. In certain cases, although by no means frequently, mixed cryoglobulins are associated with a vasculitis that produces a spectrum of manifestations resembling those of experimental serum sickness. Therefore, we propose a set of criteria to be used as the starting point for establishing a definitive diagnosis. The next step in the classification of cryoglobulinemic syndromes is to define the primary or secondary nature of the disease process and the mono- or polyclonal nature of the rheumatoid factor. Finally, the extent of the vasculitis must be assessed by screening for liver and renal involvement and peripheral neuropathy. Despite the high prevalence of HCV markers in both the primary and secondary forms, we believe our classification is useful for characterizing groups of patients with different diseases and different prognoses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8730492

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  Purpura and serum mixed cryoglobulinemia in psoriatic arthritis.

Authors:  Carlo Palazzi; Emilio D'Amico; Ernesta Pennese; Attilio Petricca; Ignazio Olivieri
Journal:  Rheumatol Int       Date:  2006-08-10       Impact factor: 2.631

Review 2.  Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polyarteritis nodosa and hepatitis C virus associated cryoglobulinemic vasculitis.

Authors:  Aman Sharma; Kusum Sharma
Journal:  J Clin Exp Hepatol       Date:  2013-07-08

3.  Preliminary classification criteria for the cryoglobulinaemic vasculitis.

Authors:  S De Vita; F Soldano; M Isola; G Monti; A Gabrielli; A Tzioufas; C Ferri; G F Ferraccioli; L Quartuccio; L Corazza; G De Marchi; M Ramos Casals; M Voulgarelis; M Lenzi; F Saccardo; P Fraticelli; M T Mascia; D Sansonno; P Cacoub; M Tomsic; A Tavoni; M Pietrogrande; A L Zignego; S Scarpato; C Mazzaro; P Pioltelli; S Steinfeld; P Lamprecht; S Bombardieri; M Galli
Journal:  Ann Rheum Dis       Date:  2011-05-13       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.